Sec Form 3 Filing - Koneru Mythili @ Marker Therapeutics, Inc. - 2019-05-09

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Koneru Mythili 2. Issuer Name and Ticker or Trading Symbol Marker Therapeutics, Inc. [ MRKR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Snr VP, Clinical Development (Last) (First) (Middle) 3200 SOUTHWEST FREEWAY, SUITE 2240 3. Date of Earliest Transaction (MM/DD/YY) 05/09/2019 (Street) HOUSTON, TX77027 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (Right to Buy) ( 1 ) $ 5.1 ( 1 ) 02/07/2029 Common Stock 10,000 D Employee Stock Option (Right to Buy) ( 2 ) $ 5.1 ( 2 ) 02/07/2029 Common Stock 300,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Koneru Mythili 3200 SOUTHWEST FREEWAY SUITE 2240 HOUSTON, TX77027 Snr VP, Clinical Development Signatures /s/ Mark A. Catchur as Attorney-In-Fact for Mythili Koneru* 05/15/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended for service as the Company's Senior Vice President, Clinical Development which vested immediately. The option exercise price is the closing price on the date of the grant, February 7, 2019. ( 2 )Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended for service as the Company's Senior Vice President, Clinical Development. One quarter of the shares vest on the first anniversary of the grant date, the remainder of the shares vest in monthly installments over a three year period upon the continued employment of the Reporting Person by the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, February 7, 2019.

Remarks: * Mr. Mark A. Catchur is signing as Attorney-in-Fact pursuant to power of attorney dated May 9, 2019 granted by the Reporting Person, a copy of which is filed as an exhibit and incorporated herein by reference.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.